Search research articles
Contact Us
Filters
Showing results (31-40 of 61) with videos related to
Page
of 7
Sort By:
Diabetes Care
|
August 1, 2014
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)
Matthew C Riddle, Geremia B Bolli, Monika Ziemen, et al.
Diabetes Care
|
March 6, 2014
Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs
Philip D Home, Chunduo Shen, Mohammad I Hasan, et al.
Diabetes Care
|
July 26, 2014
Response to comment on Home et al. Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. Diabetes Care 2014;37:1237-1245
Philip D Home, Chunduo Shen, Mohammad I Hasan, et al.
Obstetrics and Gynecology International
|
June 12, 2012
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
Jacques Lepercq, Jay Lin, Gillian C Hall, et al.
Diabetes, Obesity & Metabolism
|
June 30, 2017
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes Care
|
June 19, 2015
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes, Obesity & Metabolism
|
December 7, 2018
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0
David R Owens, Wolfgang Landgraf, Brian M Frier, et al.
Diabetes, Obesity & Metabolism
|
August 17, 2021
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison
Philip D Home, Roopa Mehta, Khadija A S Hafidh, et al.
Diabetes, Obesity & Metabolism
|
October 30, 2022
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
Philip D Home, Rory J McCrimmon, Julio Rosenstock, et al.
Diabetes Care
|
April 25, 2009
Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study
Geremia B Bolli, David Kerr, Reena Thomas, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 61) with videos related to
Sort By:
Page
of 7
Diabetes Care
|
August 1, 2014
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)
Matthew C Riddle, Geremia B Bolli, Monika Ziemen, et al.
Diabetes Care
|
March 6, 2014
Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs
Philip D Home, Chunduo Shen, Mohammad I Hasan, et al.
Diabetes Care
|
July 26, 2014
Response to comment on Home et al. Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. Diabetes Care 2014;37:1237-1245
Philip D Home, Chunduo Shen, Mohammad I Hasan, et al.
Obstetrics and Gynecology International
|
June 12, 2012
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
Jacques Lepercq, Jay Lin, Gillian C Hall, et al.
Diabetes, Obesity & Metabolism
|
June 30, 2017
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes Care
|
June 19, 2015
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes, Obesity & Metabolism
|
December 7, 2018
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0
David R Owens, Wolfgang Landgraf, Brian M Frier, et al.
Diabetes, Obesity & Metabolism
|
August 17, 2021
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison
Philip D Home, Roopa Mehta, Khadija A S Hafidh, et al.
Diabetes, Obesity & Metabolism
|
October 30, 2022
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
Philip D Home, Rory J McCrimmon, Julio Rosenstock, et al.
Diabetes Care
|
April 25, 2009
Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study
Geremia B Bolli, David Kerr, Reena Thomas, et al.
Page
of 7